ClinicalTrials.gg
RecruitingNCT02410850Updated Jan 23, 2024

Long Term Oral Appliance Therapy Effectiveness for Obstructive Sleep Apnea Syndrome

An observational study in Obstructive Sleep Apnea, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Apr 2018; still recruiting 8 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Sleep Apnea, Obstructive by University of British Columbia — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea, Obstructive · University of British Columbia.

Started
2018
with 3 others
Observational
2 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Sleep Apnea, Obstructive by University of British Columbia, this one is one of 4 that started in 2018, is one of 2 observational ones, and was the 8th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

4 of the 16 studies in Sleep Apnea, Obstructive by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Apnea, Obstructive by University of British Columbia, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is a highly prevalent breathing problem that occurs during sleep. OSA have been associated with the obesity epidemic in developing countries; additionally, high OSA prevalence rates are present in populations with cardiovascular and metabolic disorders. Two OSA treatments are currently available, oral appliance (OA) therapy and continuous positive airway pressure (CPAP). OAs are an underutilized non-surgical treatment and few studies have analyzed their long-term effectiveness for patients with OSA. The purpose of this study is to assess the long-term effectiveness of OA therapy in patients with OSA and to explore any changes on cardiovascular related morbidity and mortality related to this therapy.

Read the detailed description

Obstructive sleep apnea (OSA) is a chronic condition which may occur when an individual is sleeping. OSA incidence rates ranges from 4 to 16% of the adult population. The prevalence of OSA is even higher in populations with cardiovascular and metabolic disorders (e.g. stroke or diabetes mellitus).

OSA is characterized by five or more pauses in breathing per hour or partial obstruction of airway during sleep.

Obstructive sleep apnea (OSA) is currently being treated using two methods: oral appliance (OA) therapy and continuous positive airway pressure (CPAP). Although the American Academy of Sleep Medicine (AASM) has approved both methods as a first line treatment for mild and moderate OSA, oral appliances have been underutilized despite their non-invasive, quietness, the fact they are non-surgical and, cost effectiveness. OAs can also be an alternative for severe OSA patients who find CPAP treatment intolerable. There are two major groups of OAs available, one that acts on repositioning the mandible and tongue; this includes mandibular advancement splints (MAS) and Mandibular advancement devices (MAD). The other group of OAs, tongue retaining devices (TRD) focus on holding the tongue forward. It is because of the positioning of the tongue and mandible that OAs is effective in decreasing sleep apnea. OA therapy is a long-term treatment and therefore it is important that the appliance be comfortable to encourage patient use.

Despite the benefits to patients using OAs, previous studies have not looked at the relationship between OAs and OSA in long term studies or in a large number of patients. This lack of research and knowledge has led to an absence in training and education for dentists who are able to provide OA therapy to their patients. OAs have been shown to not be as effective as CPAP in helping with OSA, however, it has similar effects on blood pressure, quality of life, sleepiness and endothelial function. Previous studies have shown that the effects of OA therapy on patients' OSA are associated with more acceptance and adherence. Previous longitudinal studies that followed patients using CPAP showed great benefits in terms of cardiovascular health. It is therefore necessary for large sample size, long term prospective cohort studies to be done to determine how effective OA therapy is for patients with OSA, while also looking at potential effects on cardiovascular morbidity and mortality. It is for this reason that 15 centres from 9 counties around the world have formed a network called ORANGE (Oral Appliance Network on Global Effectiveness) dedicated on the long-term outcomes of OAs.

These centers included: University of Sidney (Australia), Stanford University (USA). Kaiser Permanente (USA), Cambridge University (UK), Paris Hospital (France), University of Antwerp (Belgium), Japan Somnology Center (Japan), Kyushu University (Japan), University of British Columbia (Canada), University of Montreal (Canada), Laval University (Canada), University of Gronigen (Netherlands), and Umea University (Sweden).

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Oral Appliance
  • objective adherence
  • cardiovascular events
  • cardiovascular mortality
  • cerebrovascular mortality
  • cost effectiveness
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who seek Oral Appliance therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are currently prescribed Oral Appliance for their Obstructive Sleep Apnea

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18 years.
  • Patients that do not understand the English language.
  • Patients that refuse to sign the for any reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • University of Montreal

    Patients from University of Montreal in Canada

    Device: Oral Appliance

  • University of Antwerp

    Patients from University of Antwerp in Belgium.

    Device: Oral Appliance

  • University of Sydney

    Patients from University of Sydney in Australia.

    Device: Oral Appliance

  • Angers University Hospital

    Patients from Angers University Hospital in France.

    Device: Oral Appliance

  • University of Gronigen

    Patients from University of Gronigen in Netherlands.

    Device: Oral Appliance

  • Kaiser Permanente

    Patients from Kaiser Permanente from USA.

    Device: Oral Appliance

  • Stanford University

    Patients from Stanford University from USA.

    Device: Oral Appliance

  • Laval University

    Patients from Laval University in Canada.

    Device: Oral Appliance

  • Cambridge University

    Patients from Cambridge University in UK.

    Device: Oral Appliance

  • Kyushu University

    Patients from Kyushu University in Japan

    Device: Oral Appliance

  • Japan Somnology Center

    Patients from Japan Somnology Center in Japan.

    Device: Oral Appliance

  • Uniformed Services University

    Patients from the Uniformed Services University in USA.

    Device: Oral Appliance

  • University of British Columbia

    Patients from the University of British Columbia in Canada.

    Device: Oral Appliance

Interventions

  • DeviceOral Appliance

    Mandibular Advancement Splints

06

What researchers measure

Primary outcomes

  1. Long term effectiveness of Oral Appliance therapy by assessing responses to treatment specific questionnaires and other questionnaires such as Functional Outcomes of Sleep Questionnaire (FOSQ), Epworth Sleepiness Scale(ESS), and Short Form 36 (SF-36)

    Time frame: 5 years

  2. Impact of Oral Appliance therapy on cardiovascular morbidity by assessing health changes, hospitalizations and number of deaths during treatment with Oral Appliance

    Time frame: 5 years

  3. Impact of Oral Appliance therapy on cardiovascular mortality by assessing health changes, hospitalizations and number of deaths during treatment with Oral Appliance

    Time frame: 5 years

Secondary outcomes

  1. Objective adherence by assessing Oral Appliance adherence chip data

    Time frame: 1,3,5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Sep 2026, 101 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 101 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2015
First posted
Apr 8, 2015
StartActual
Apr 1, 2018
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02410850
Collaborators
Universiteit Antwerpen, University of Sydney, University Hospital, Angers, University of Groningen, Université de Montréal, Kaiser Permanente, Stanford University, Laval University, University of Cambridge, Kyushu University, Japan Somnology Center, Neuropsychiatric Research Institute, Uniformed Services University of the Health Sciences
Responsible party
Fernanda Almeida (Principle Investigator, University of British Columbia) — Principal investigator
First posted
Apr 8, 2015
Start date
Apr 1, 2018
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jan 23, 2024

Study contacts

Fernanda Almeida, DDS,PhD
Contact
falmeida@dentistry.ubc.ca
604-822-3623
Mary Wong
Contact
mwong@dentistry.ubc.ca
604-827-0690
Fernanda Almeida, DDS,Phd
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion